Cleerly Stock

cleerlyhealth.comHealthcare / Digital HealthFounded: 2017Funding to Date: $386.48MM

Cleerly is a healthcare technology company which offers AI-based digital care platforms designed for the evaluation and treatment of heart disease to healthcare providers. Their platform analyzes coronary computed tomography angiography (CCTA) imaging to identify and quantify atherosclerosis, aiming to enable potentially earlier and more precise diagnosis of heart disease. Cleerly's technology strives to provide detailed insights into plaque characteristics, with the goal of supporting personalized treatment plans for patients. This company was founded by James Min MD in 2017 and is headquartered in Denver, CO.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Cleerly, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Cleerly Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Cleerly Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
12/04/2024 Series C $330.08MM $xx.xx $729.01MM Battery Ventures, Breyer Capital, Cigna Ventures, Digitx Partners, Fidelity Management, Heartland Healthcare Capital Funds, Insight Partners, Lrvhealth, Mirae Asset Capital, New Leaf Ventures, Novartis, Peter Thiel, Piper Sandler, Pura Vida Investments, Sands Capital, T. Rowe Price Associates, Vensana Capital
Price per Share
$xx.xx
Shares Outstanding
28,019,290
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Battery Ventures, Breyer Capital, Cigna Ventures, Digitx Partners, Fidelity Management, Heartland Healthcare Capital Funds, Insight Partners, Lrvhealth, Mirae Asset Capital, New Leaf Ventures, Novartis, Peter Thiel, Piper Sandler, Pura Vida Investments, Sands Capital, T. Rowe Price Associates, Vensana Capital
06/21/2021 Series B $28.1MM $xx.xx $114.1MM Cigna Ventures, Digitx Partners, Lrvhealth, New Leaf Venture Partners, The American College Of Cardiology, Vensana Capital
Price per Share
$xx.xx
Shares Outstanding
8,408,926
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Cigna Ventures, Digitx Partners, Lrvhealth, New Leaf Venture Partners, The American College Of Cardiology, Vensana Capital
06/21/2021 Series B-1 $16.8MM $xx.xx $114.1MM Cigna Ventures, Digitx Partners, Lrvhealth, New Leaf Venture Partners, The American College Of Cardiology, Vensana Capital
Price per Share
$xx.xx
Shares Outstanding
3,853,457
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Cigna Ventures, Digitx Partners, Lrvhealth, New Leaf Venture Partners, The American College Of Cardiology, Vensana Capital
08/10/2017 Series A $11.49MM $xx.xx $32.84MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
3,439,646
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors

Cleerly Investors Also Invested in These Private Companies

Digitx Partners
Impact Assets
The American College Of Cardiology
Catalytic Impact Foundation
Heartland Healthcare Capital Funds
New Leaf Ventures

Leadership & Board

Leadership

James Min MD
Founder, Chief Executive Officer, President & Board Member
Krissy Wright
Chief Financial Officer
Joseph Jasser MD
Chief Operating Officer
Kimberly McCombs
Chief Strategy Officer
Nick Nieslanik
Chief Technology Officer
Zach Hong
Chief Compliance Officer & General Counsel
Jim Hartman
Chief Revenue Officer
Udo Hoffmann MD
Chief Scientfic Officer
James Earls MD
Chief Medical Officer
Kristin Binns
Chief Marketing & Communications Officer

Board

Glenn Steele Ph.D
LRVHealth
Justin Klein MD
Vensana Capital
Tripp Peake III
LRVHealth
Vijay Lathi
New Leaf Venture

Cleerly stock FAQs

plusminus

Can you buy Cleerly stock?

As Cleerly is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Cleerly, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Cleerly stock?

To invest in a private company like Cleerly through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Cleerly stock?

Yes, you may sell the Cleerly stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Cleerly stock?

If you hold private company shares of Cleerly – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Cleerly on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Cleerly a public company?

No, Cleerly is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Cleerly’s stock price?

Cleerly is a privately held company and therefore does not have a public stock price. However, you may access Cleerly private market stock price with Forge Data.
plusminus

What is Cleerly’s stock ticker symbol?

Cleerly does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Cleerly News and Media Highlights

Cleerly raises $106M from Insight Partners for AI heart health early detection

Cleerly announced that it raised a $106 million Series C extension round led by Insight Partners and joined by Battery Ventures. The large capital haul comes a little over two years after Cleerly raised a $223 million Series C led by T. Rowe Price and Fidelity. The company’s software has been available commercially for the last four years, and over that period, Cleerly has had a compounded annual growth of over 100%.

Cleerly Uses an AI-Based Digital Platform to Transform Heart Disease Diagnosis

Digital healthcare company Cleerly is leveraging AI technology to revolutionize the diagnosis of heart disease. Their platform uses imaging and AI to detect atherosclerosis at an early stage, enabling more personalized and effective treatment plans. The company is also sponsoring a trial, TRANSFORM, to validate the efficacy of this personalized care strategy.

How AI is detecting heart attack risk and aiming to outsmart America’s No. 1 killer

Cardiologist James Min, former professor at Weill Cornell Medical College and director of the Dalio Institute of Cardiovascular Imaging at New York-Presbyterian, founded Cleerly to find a better way to assess heart health, by applying AI to the problem, cutting down on the time it takes to flag issues and ultimately reach his goal of a “heart-attack free” world.

Cleerly raises nearly $200 mln in fundraise led by T. Rowe Price, Fidelity

Cleerly, a New York-based health tech startup, has raised $192 million in a funding round led by investment firms T. Rowe Price (TROW.O) and Fidelity Management & Research Company LLC.
Browse Insights
Updated on: Dec 22, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.